DIAM Spinal Stabilization System
Companion Spine France Sas · Decision date Apr 1, 2026
What did the FDA approve?
FDA records P240043/S001 as a supplement to PMA P240043, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Apr 1, 2026.
FDA approval order statement
Approval for a shelf-life extension from 1-year to 5-years for the DIAM Spinal Stabilization System. Based upon the information submitted, the PMA supplement is approved.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Orthopedic
- Decision date
- Apr 1, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P240043/S001
- Regulatory pathway
- PMA supplement
- Applicant
- Companion Spine France Sas
- Product code
- NQO
- Decision code
- APPR
- Decision date
- Apr 1, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, spinous process spacer/plate.
- Applicant
- Companion Spine France Sas
- Product code
- NQO
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240043. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240043 · Original PMA
DIAM Spinal Stabilization System
P240043/S001 received
Application receipt date recorded by FDA.
P240043/S001 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P240043. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240043
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Companion Spine France Sas | PMA approval | Dec 10, 2025 | FDA |
Explore the linked device profile
Other records with product code NQO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
coflex Interlaminar TechnologyP110008/S015 | Companion Spine France | PMA supplement | May 22, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Companion Spine France Sas
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Immeuble Le Bridge 5, 5 Allee Des Acacias, Merignac, 33 700
Sources and methodology
- Original FDA record: P240043/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
